Mabrix 100 iv is a brand of rituximab, a cytotoxic immunosuppressant given as an injection. It is a monoclonal antibody used in the treatment of certain lymphomas, and it is given under specialist supervision.
There are 2 brands of Rituximab listed in Bangladesh. By unit price, Mabrix 100 iv is among the cheapest of them.
What is Mabrix 100 iv 10 mg/ml Injection?
Mabrix 100 iv is a prescription injection containing rituximab, a type of medicine called a cytotoxic immunosuppressant. It is a monoclonal antibody that targets a specific marker on certain white blood cells. Doctors use it to treat some forms of non-Hodgkin's lymphoma. Because it affects the immune system and can cause serious reactions, it is given in a hospital or clinic setting by healthcare professionals. The dose and course are decided by the doctor based on the patient's condition.
Uses of Mabrix 100 iv
Mabrix 100 iv is used to treat non-Hodgkin's lymphoma, a cancer of the lymphatic system. It may be given alone or in combination with chemotherapy, depending on the type and stage of the disease. It is also used as maintenance therapy in some patients who respond to initial treatment. Your doctor will decide if this medicine is suitable for you.
How to use Mabrix 100 iv
Mabrix 100 iv is given as an intravenous infusion by a healthcare professional, usually in a hospital or clinic. The dose, infusion rate and course are decided by the doctor and may be adjusted based on your response and side effects. You should not attempt to inject this medicine yourself. Follow all instructions given by your doctor and nurse.
Side effects of Mabrix 100 iv
Common side effects include fever, chills, itching, skin rash, flushing, low blood pressure, headache, and tiredness. More serious effects can include breathing difficulties, heart problems, low blood counts, and liver problems. Some patients may experience hepatitis B reactivation. Tell your doctor promptly if you notice any unusual symptoms during or after the infusion.
Safety and precautions
Before receiving Mabrix 100 iv, tell your doctor if you have a history of heart disease, lung problems, or a large tumour burden, as extra monitoring may be needed. This medicine is not recommended during pregnancy unless the doctor decides the benefit outweighs the risk, and it should not be used while breastfeeding. It is also not for people with severe active infections or known allergy to mouse proteins. Always inform your doctor about all medicines you take and any health conditions you have.
Frequently asked questions
What is Mabrix 100 iv used for and what kind of medicine is it?
Mabrix 100 iv is a cytotoxic immunosuppressant injection containing rituximab. It is used to treat certain types of non-Hodgkin's lymphoma, either alone or with chemotherapy. It works by targeting specific immune cells. Your doctor will advise if it is right for you.
How should Mabrix 100 iv be taken?
Mabrix 100 iv is given as an intravenous infusion by a healthcare professional in a hospital or clinic. The dose and schedule are decided by your doctor and may be adjusted during treatment. Do not try to inject it yourself.
What medicines may interact with Mabrix 100 iv?
Mabrix 100 iv may interact with cisplatin, increasing the risk of kidney toxicity. It should not be given with live viral vaccines. Tell your doctor about all medicines you are taking, including over-the-counter products, before starting treatment.
Who should avoid Mabrix 100 iv?
Mabrix 100 iv should not be used by people with a known allergy to mouse proteins, active severe infections, or severely weakened immune systems. It is also not recommended during breastfeeding. Always discuss your medical history with your doctor before treatment.
Non-Hodgkin's Lymphoma (NHL): Rituximab is indicated for the treatment of patients with-
Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
... Read more
Non-Hodgkin's Lymphoma (NHL): Rituximab is indicated for the treatment of patients with-
Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Chronic Lymphocytic Leukemia (CLL): Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid Arthritis (RA): Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Granulomatos Is With Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA): Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) andMicroscopic Polyangiitis (MPA).
Pharmacology
Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.
Duration: Detectable in serum 3-6 mth after completion of therapy; B-cell recovery 6-12 mth following completion of therapy.
Dosage & Administration
Intravenous (Adult)-
Non-Hodgkin's lymphoma, Refractory or relapsed follicular lymphoma: As a single agent, 375 mg/m2 infusion once wkly, for 4 doses at an initial rate of 50 mg/hr. May increase by 50 mg/hr every 30 min. If tolerated, subsequent infusions can be started at 100 mg/hr and increased by 100 mg/hr every 30 min. Max rate: 400 mg/hr. When used with CVP (cyclophosphamide, vincristine and prednisolone) for follicular lymphoma or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) for diffuse large B-cell lymphoma, 375 mg/m2 given on day 1 of the chemotherapy cycle after corticosteroid regimen, for up to 8 cycles. For patients who were treated with 6-8 cycles of CVP chemotherapy and have not progressed, 375 mg/m2 may be given once wkly for 4 doses, may repeat every 6 mth, for up to 16 doses. Maintenance: 375 mg/m2 given once every 3 mth (those who have responded to induction chemotherapy), once every 2 mth initiated 2 mth after the last dose of induction chemotherapy (previously untreated) for a max period of 2 yr.
Chronic lymphocytic leukaemia: 375 mg/m2, given on the day prior to chemotherapy in cycle 1, followed by 500 mg/m2 on day 1 (every 28 days) of cycles 2-6.
Rheumatoid arthritis: Given as two 1 g IV infusion doses, separated by 2 wk and in combination with methotrexate. Corticosteroids may be given before each infusion to minimise the risk and severity of infusion reactions.
Interaction
Increased risk of renal toxicity with cisplatin.
Contraindications
Hypersensitivity to murine proteins. Patients with active, severe infections. Severely immunocompromised state. Concomitant use with live viral vaccines. Lactation.
Side Effects
Reactivation of hepatitis B virus. Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. Exacerbation of heart failure and angina pectoris. Reversible interstitial pneumonia and interstitial fibrosis. Depletion of immunoglobulin concentrations.
Pregnancy & Lactation
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Precautions & Warnings
Extensive tumour burden, pulmonary insufficiency or pulmonary tumour infiltration; history of cardiac disease. Pregnancy.
Storage Conditions
Store between 2-8° C.
Alternative brands of Rituximab
Other brands with the same generic name, cheapest first.